Biogen (BIIB) Operating Leases (2018 - 2026)

Biogen (BIIB) has reported Operating Leases for 9 consecutive years, with $273.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 15.46% year-over-year to $273.4 million; the TTM figure through Mar 2026 stood at $273.4 million (down 15.46% YoY), while the FY2025 annual figure was $290.4 million, down 31.0% from the prior year.
• Operating Leases came in at $273.4 million for Q1 2026 at Biogen, down from $290.4 million in the prior quarter.
• The five-year high for Operating Leases was $490.3 million in Q4 2023, with the low at $273.4 million in Q1 2026.
• Average Operating Leases over 5 years is $351.6 million, with a median of $327.0 million recorded in 2023.
• Across the five-year window, Operating Leases soared 30.21% in 2022 and plunged 31.0% in 2025, its largest moves.
• Year by year, Operating Leases stood at $430.2 million in 2022, then increased by 13.97% to $490.3 million in 2023, then retreated by 14.15% to $420.9 million in 2024, then slumped by 31.0% to $290.4 million in 2025, then fell by 5.85% to $273.4 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $273.4 million, $290.4 million, and $305.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.